Net sales rose 6.9% in Q2 and 26.2% for H1, but higher costs from investments led to negative operating results. Vimab expects a return to profit in Q3 and remains well positioned in energy infrastructure megatrends.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.